All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PF-05251749
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Biogen
Deal Size: $710.0 million Upfront Cash: $75.0 million
Deal Type: Acquisition January 13, 2020
Details:
With this purchase, Biogen plans to develop the Phase 1 asset for the treatment of Sundowning in Alzheimer’s disease (AD) and Irregular Sleep Wake Rhythm Disorder in Parkinson’s disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LP352
Therapeutic Area: Neurology Product Name: LP352
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Arena Pharmaceuticals
Deal Size: $56.0 million Upfront Cash: Undisclosed
Deal Type: Financing October 28, 2020
Details:
Proceeds from the financing will be used to support the development of LP352 for treatment-resistant developmental and epileptic encephalopathies, and preclinical programs relating to LP143 and LP659 for the potential treatment of microglial neuroinflammatory diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Leronlimab
Therapeutic Area: Neurology Product Name: PRO 140
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
Company is accelerating the filing of a Ph2 protocol to evaluate leronlimab’s potential as a therapeutic for stroke recovery. Administration of leronlimab resulted in approx. 70-75% CCR5 receptor occupancy in the Brain.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Diazepam
Therapeutic Area: Neurology Product Name: XP-0863
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2020
Details:
The FDA provided feedback that Xeris’ drug development program for XP-0863 could advance directly into a Phase 3 registration study in both pediatric and adult patients with epilepsy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ACD856
Therapeutic Area: Neurology Product Name: ACD856
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
The abstract demonstrates that AlzeCure's leading drug candidate in the company's NeuroRestore platform, ACD856, has the potential for wide use in various types of cognitive memory disorders.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NBI-921352
Therapeutic Area: Neurology Product Name: XEN901
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Xenon Pharmaceuticals Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
U.S. Food and Drug Administration (FDA) Requests Additional Non-Clinical Data to Support Dose Justification Before Initiation of a Phase II Clinical Trial with NBI-921352 in Pediatric SCN8A-DEE Patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DNL151
Therapeutic Area: Neurology Product Name: DNL151
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Biogen
Deal Size: $2,150.0 million Upfront Cash: $560.0 million
Deal Type: Licensing Agreement October 07, 2020
Details:
The companies will co-develop Denali’s small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson’s disease, and will co-commercialize Denali’s LRRK2 products in the United States and China, with shared responsibility for worldwide development costs.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KCP-506
Therapeutic Area: Neurology Product Name: KCP-506
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 07, 2020
Details:
With the extension, Kineta will continue development of α9/α10 nicotinic acetylcholine receptor (nAChR) antagonists and will advance KCP506 through Phase 1 clinical trials. Kineta will also receive an undisclosed payment from Genentech to extend the research collaboration.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): XPro1595
Therapeutic Area: Neurology Product Name: XPro1595
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
Details:
The preliminary data, albeit in a small number of patients, demonstrate that XPro1595, when given via subcutaneous injection, decreases neuroinflammation in the arcuate fasciculus.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LTI-291
Therapeutic Area: Neurology Product Name: BIA 28-6156
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: BIAL
Deal Size: $130.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition October 01, 2020
Details:
BIAL has established a new affiliate in the U.S BIAL Biotech Investments Inc. Additionally, BIAL has acquired worldwide rights of LTI-291 and all the Parkinson’s disease research programs of Lysosomal Therapeutics and taken on the entire R&D team.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
